Kennedy, who has faced opposition from health groups and Democrats, has long sown doubts about the safety and efficacy of ...

The U.S. Senate Finance Committee on Tuesday voted in favor of advancing the nomination of Robert F. Kennedy Jr. to lead the ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $428 million specializing in mRNA therapeutics and vaccines, stands at a ...

It’s time for a new era of public health—where vaccines are seen as both a scientific triumph and a shared commitment to well ...

Robert F. Kennedy, Jr. will begin Senate confirmation hearings on Wednesday as President Donald Trump's pick to lead the Department of Health and Human Services.

Every time a shuttle docks with the International Space Station (ISS), a delicate dance unfolds between the shuttle's docking ...

Based on the long-standing collaboration between Merck and Moderna, as well as the incredibly favorable initial efficacy data for ... Moderna has filed suit against Pfizer and BioNTech in the ...

The company did however find relatively low vaccine efficacy ... the Moderna vaccine in these age groups. Last month, the FDA postponed a meeting of a panel to consider the Pfizer-BioNTech Covid ...

Moderna's mRESVIA joined the market after RSV vaccines from Pfizer and GSK already had established themselves. At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $ ...

Moderna's mRESVIA must contend with Abrysvo from Pfizer and Arexvy from GSK ... for a norovirus vaccine candidate that could produce efficacy data this year, depending on how rapidly new cases ...

Aside from Pfizer, other companies were also asked if they expect any changes from the incoming administration on vaccines. The CEO of Moderna, which created the mRNA Covid vaccine, and has other ...